pharmaceuticals Archives - CFO

Pharma CFO Anthony Doyle Plans for Uncertainty

Pharma CFO Anthony Doyle Plans for Uncertainty

"People have a higher appetite for risk, knowing that they can do a lot of good," the BioCryst Pharmaceuticals CFO said.

By Vincent Ryan | April 21, 2022

Merck, Sanofi in Deals for Cancer Drug Firms

Merck, Sanofi in Deals for Cancer Drug Firms

The pharma giants each announced they would buy smaller drugmakers to expand cancer-treatment franchises.

By Lauren Muskett | December 9, 2019

SEC Charges Drug Firm with Reg FD Violations

Risk & Compliance

SEC Charges Drug Firm with Reg FD Violations

In calls and emails, TherapeuticsMD shared material, nonpublic information about a new drug's likelihood of FDA approval with sell-side analysts.

By Vincent Ryan | August 20, 2019

DOJ Puts C-Suite Execs in Crosshairs

Risk Management

DOJ Puts C-Suite Execs in Crosshairs

DOJ: “While pursuit of criminal and civil remedies against corporations is important, we should always focus on the individuals responsible for misconduct."

By Vincent Ryan | July 10, 2019

Botox Maker Allergan Sold to AbbVie for $63B

Botox Maker Allergan Sold to AbbVie for $63B

AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.

By Lauren Muskett | June 25, 2019

J&J Gets Boost From Strong Cancer Drug Sales

Financial Performance

J&J Gets Boost From Strong Cancer Drug Sales

The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.

By Matthew Heller | October 16, 2018

Ex-Salix CFO Fined $1M for Misstating Inventory

Risk & Compliance

Ex-Salix CFO Fined $1M for Misstating Inventory

The SEC says Adam Derbyshire failed to disclose high wholesaler inventory levels of Salix's drugs resulting from its practice of overselling demand.

By Matthew Heller | October 1, 2018

Pfizer Beats Estimates on Strength in Key Drugs

Financial Performance

Pfizer Beats Estimates on Strength in Key Drugs

Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.

By Matthew Heller | July 31, 2018

Roche Takes Full Control of Genomic Profiler

Roche Takes Full Control of Genomic Profiler

The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.

By Matthew Heller | June 19, 2018

Shire Accepts Improved $62B Bid From Takeda

Shire Accepts Improved $62B Bid From Takeda

The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.

By Matthew Heller | May 8, 2018

Generic Competition Hits Pfizer’s Q2 Sales

Financial Performance

Generic Competition Hits Pfizer’s Q2 Sales

The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.

By Matthew Heller | August 2, 2017

J&J Posts $17.7B in Revenue, Misses Estimates

Financial Performance

J&J Posts $17.7B in Revenue, Misses Estimates

Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.

By Matthew Heller | April 19, 2017

J&J Boosts Drug Roster With $30B Actelion Deal

J&J Boosts Drug Roster With $30B Actelion Deal

The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.

By Matthew Heller | January 26, 2017

J&J Sales Increase 1.7% But Miss Estimates

J&J Sales Increase 1.7% But Miss Estimates

Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.

By Matthew Heller | January 24, 2017

Lonza to Buy Drug Capsule Maker for $5.5B

Lonza to Buy Drug Capsule Maker for $5.5B

The acquisition of Capsugel will enable Lonza to offer an integrated menu of drug delivery products.

By Matthew Heller | December 15, 2016